Results 231 to 240 of about 786,314 (373)

A comprehensive study on drug-related Raynaud's phenomenon based on the FDA adverse event reporting system. [PDF]

Sci Rep
Zheng P, Zheng X, Chen Q, Wang D, Huang L, Lin J, Chen S.   +6 more
europepmc   +1 more source

Torsades de pointes and QT prolongation Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System [PDF]

, 2019
Chengwen Teng, Elizabeth Walter, Daryl Kevin S. Gaspar, Obiageri O. Obodozie-Ofoegbu, Christopher R. Frei   +4 more
openalex   +1 more source

Engineering Strategies for 2D Layered Tin Halide Perovskite Field‐Effect Transistors

Advanced Functional Materials, EarlyView.
2D halide perovskites are promising candidates for field‐effect transistor (FET) applications due to their high stability and suppressed ion migration in the presence of bulky organic spacers. This review systematically summarizes the optimization engineering strategies of 2D perovskite FETs and future challenges, which provide guidance for developing ...
Shuanglong Wang, Zhitian Ling, Paul W. M. Blom, Tomasz Marszalek, Wojciech Pisula   +4 more
wiley   +1 more source

Case series of reports of pruritus and sipuleucel-T submitted to the Food and Drug Administration Adverse Event Reporting System [PDF]

, 2019
Graça M. Dores, Silvia Pérez-Vilar, Manette T. Niu   +2 more
openalex   +1 more source

Pulmonary arterial hypertension in breast cancer patients on HER2-targeted therapy: a review of FDA Adverse Events Reporting System data [PDF]

, 2020
Godsfavour Umoru, Matthew Taitano, Sarah Beshay, Polly Niravath, Sandeep Sahay   +4 more
openalex   +1 more source

Versatile Cell Penetrating Peptide for Multimodal CRISPR Gene Editing in Primary Stem Cells

Advanced Functional Materials, EarlyView.
CRISPR machinery in diverse molecular formats (DNA, RNA, and ribonucleic protein) is complexed into nanoparticles with the cell‐friendly arginine‐alanine‐leucine‐alanine (RALA) cell‐penetrating peptide. Nanoparticles are delivered to primary mesenchymal stem cells ex vivo or locally in vivo to facilitate multimodal CRISPR gene editing. This RALA‐CRISPR
Joshua P. Graham, Jose Gabriel Castro, Lisette C. Werba, Joseph Amitrano, Luke Fardone, Kevin P. Francis, Anand Ramamurthi, Michael J. Layden, Helen O. McCarthy, Tomas Gonzalez‐Fernandez   +9 more
wiley   +1 more source

Response to FDA Adverse Event Reporting System (FAERS) Essentials: A Reflection on Study Conception. [PDF]

Clin Pharmacol Ther
Reyes M, Potter E, Dal Pan G.
europepmc   +1 more source

Evaluation of the Association of Hand-Foot Syndrome with Anticancer Drugs Using the US Food and Drug Administration Adverse Event Reporting System (FAERS) and Japanese Adverse Drug Event Report (JADER) Databases

, 2016
Sayaka Sasaoka, Toshinobu Matsui, Junko Abe, Ryogo Umetsu, Yamato Kato, Natsumi Ueda, Yuuki Hane, Yumi Motooka, Haruna Hatahira, Yasutomi Kinosada, Mitsuhiro Nakamura   +10 more
openalex   +2 more sources

PDG98 A DISPROPORTIONALITY ANALYSIS OF SPONTANEOUS ADVERSE EVENT REPORTS FOR OSTEONECROSIS OF JAW ATTRIBUTED TO AROMATASE INHIBITORS IN FDA ADVERSE EVENTS REPORTING SYSTEM [PDF]

, 2019
N. Ravindra Reddy, K. Viswam S, Beulah Elsa Thomas, A. Bellapu, Vivek Sharma, S. Chacko   +5 more
openalex   +1 more source

PND61 Adverse Event Profiles of Therapies That Target the Calcitonin GENE-Related Peptide (CGRP) Pathway, during the First SIX Months after Launch: A Real-World DATA Analysis Using the FDA Adverse Events Reporting System (FAERS) [PDF]

, 2020
Stephen D. Silberstein, Shoshana Reshef, Joshua M. Cohen, Sanjay Gandhi, Michael J. Seminerio, Verena Ramirez-Campos, Yoel Kessler, Stephen F. Thompson, Andrew Blumenfeld   +8 more
openalex   +1 more source